title: Evaluating the impact of a disease management program for chronic complex conditions at two large northeast health plans using a control group methodology.
abstract: The objective of this study was to observe trends in payer expenditures for plan members with one of 14 chronic, complex conditions comparing one group with a disease management program specific to their condition (the intervention group) and the other with no specific disease management program (the control group) for these conditions. The authors used payer claims and membership data to identify members eligible for the program in a 12-month baseline year (October 2001 to September 2002) and a subsequent 12-month program year (October 2002 to September 2003). Two payers were analyzed: one health plan with members primarily in New Jersey (AmeriHealth New Jersey [AHNJ]), where the disease management program was offered, and one affiliated large plan with members primarily in the metro Philadelphia area, where the program was not offered. The claims payment policy for both plans is identical. Intervention and control groups were analyzed for equivalence. The analysis was conducted in both groups over identical time periods. The intervention group showed statistically significant (p < 0.01) differences in total paid claims trend and expenditures when compared to the control group. Intervention group members showed a reduction in expenditures of -8%, while control group members showed an increase of +10% over identical time periods. Subsequent analyses controlling for outliers and product lines served to confirm the overall results. The disease management program is likely responsible for the observed difference between the intervention and control group results. A well-designed, targeted disease management program offered by a motivated, supportive health plan can play an important role in cost improvement strategies for members with complex, chronic conditions.
authors.affiliation: AmeriHealth New Jersey, NJ, USA.
authors.forename: Henry
authors.initials: H
authors.lastname: Schwerner
authors.forename: Timothy
authors.initials: T
authors.lastname: Mellody
authors.forename: Allan B
authors.initials: AB
authors.lastname: Goldstein
authors.forename: Daryl
authors.initials: D
authors.lastname: Wansink
authors.forename: Virginia
authors.initials: V
authors.lastname: Sullivan
authors.forename: Stephan N
authors.initials: SN
authors.lastname: Yelenik
authors.forename: Warwick
authors.initials: W
authors.lastname: Charlton
authors.forename: Kelley
authors.initials: K
authors.lastname: Lloyd
authors.forename: Ted
authors.initials: T
authors.lastname: Courtemanche
mesh_terms: D016022:Case-Control Studies; D002908:Chronic Disease / Q000191:economics / Q000628:therapy*; D019468:Disease Management; D017048:Health Care Costs; D006801:Humans; D007250:Inflation, Economic; D008329:Managed Care Programs / Q000191:economics*; D009515:New Jersey; D015143:Philadelphia; D015397:Program Evaluation